Gilead Files For Approval Of Sofosbuvir For Use In Hepatitis C Treatment In Japan
This article was originally published in PharmAsia News
Executive Summary
Gilead Sciences has filed for approval of orally administered sofosbuvir for the treatment of hepatitis C in Japan, the company announced on June 27.